Vonapanitase (formerly PRT-201), is a
recombinant human Chymotrypsin-like Elastase family member 1 (CELA1) and was
previously described as type I pancreatic elastase.
This novel drug is
currently in Phase 3 human clinical trials (PATENCY-1 and PATENCY-2) in CKDpatients undergoing AVF placement (clinicaltrials.gov; NCT02110901 andNCT02414841). The goal of the clinical trials is to establish the safety
profile of vonapanitase and determine if vonapanitase applied to the outflow
vein at the time of AVF creation can improve the success and longevity of AVF
surgery. After vessel injury from AVF surgery there is often the development of
neointima hyperplasia from smooth muscle-like cells that migrate to the vessel
intima. This neointimal hyperplasia can progress to stenosis or occlusion and
cause AVF maturation failure which is a huge clinical problem. Read more>>>>>>>>>>>
No comments:
Post a Comment